AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study

September 2021 | Volume 20 | Issue 9 | Original Article | 980 | Copyright © September 2021


Published online August 16, 2021

John Joseph MD,a Amir Moradi MD MBA,b Z. Paul Lorenc MD FACS,c Kyle Coleman MD,d Glynis Ablon MD FAAD,e Joely Kaufman-Janette MD,f Sue Ellen Cox MD,g Andrew Campbell MD,h Steven Dayan MD,i Anna-Karin Berg PhD,j Girish Munavalli MD MHS FACMSk

aClinical Testing of Beverly Hills, Encino, CA
bMoradi M.D., Vista, CA
cLorenc Aesthetic Plastic Surgery Center, New York, NY
dEtre Cosmetic Dermatology and Laser Center, New Orleans, LA
eAblon Skin Institute and Research Center, Manhattan Beach, CA
fSkin Research Institute, LLC, Coral Gables, FL
gAesthetic Solutions, PA, Chapel Hill, NC
hQuintessa Aesthetic Center – Ethiq2 Research, LLC, Mequon, WI
iDeNova Research, Chicago, IL
jGalderma, Uppsala, Sweden
kDermatology, Laser & Vein Specialists of the Carolinas, PLLC, Charlotte, NC




100 and 125 U treatment was 80.0%, 88.8%, 90.0% and 95.1%, respectively, versus 2.6% with placebo (P<0.001; Figure 1). '

Secondary Efficacy Endpoints
Figure 2A shows the ILA responder rate at all post-treatment visits for subjects scoring 0 (none) or 1 (mild) at maximum frown. Respective day 2 responder rates with ABO 50, 75, 100, and 125 U were 41.3%, 46.3%, 56.3%, and 53.1%, versus 5.1% with placebo (P<0.001). Week 4 ABO responder rates with ABO 50, 75, 100, and 125 U were 92.5%, 96.3%, 97.5%, and 100%, respectively, versus 5.1% with placebo (P<0.001). Week 24 respective responder rates with ABO 50, 75, 100, and 125 U were 21.3%, 36.3%, 21.3%, and 32.1%, versus 2.6% with placebo (P<0.001). Respective week 36 responder rates with ABO 50, 75, 100 and 125 U were 5.0% (P=0.120), 10.0% (P=0.007), 8.8% (P=0.014), and 12.3% (P=0.001), versus 0 with placebo. Similar results were reported for SSA scale assessments (Figure 2B).

Figure 3 shows ILA responder rates for subjects achieving ≥1-grade improvement from baseline. Respective day 2
Close Menu